Pharmacovigilance — MCQs

10 questions

Pharmacodynamics deals with:-

A pregnant female at 37 weeks of gestation with a history of prosthetic heart valves is currently taking warfarin. She comes for a routine antenatal check-up. What is the appropriate management advice?

A female patient of childbearing age is on valproate for JME. Which drug should be used to replace valproate and can be prescribed as monotherapy?

Caution is taken while doing Inter-maxillary Fixation (IMF) for which of these types of patients?

Which study design is most effective for investigating rare adverse effects of a drug?

What is the most common gastrointestinal side effect of oral contraceptives?

Therapeutic drug monitoring is done for:

ASA classification is done for – a) Status of patient b) Risk c) Pain d) Lung disease

Q10

A 30-year-old woman is diagnosed with gonorrhea and reports a penicillin allergy (rash). Which alternative treatment regimen is most appropriate?

Pharmacovigilance Indian Medical PG Practice Questions and MCQs

Question 1: Pharmacodynamics deals with:-

A. Latency of onset
B. Mechanism of action of a drug (Correct Answer)
C. Transport of drug across the biological membranes
D. Mode of excretion of a drug

Explanation: Detailed study of the **Mechanism of action of a drug** [1][2] - **Pharmacodynamics** describes what the **drug does to the body**, including its **molecular targets** and biochemical effects [3]. - This involves the study of the drug's mechanisms to produce its therapeutic or toxic effects [2]. *Latency of onset* - **Latency of onset** refers to the time it takes for a drug to start producing its effects, which is a pharmacokinetic rather than a pharmacodynamic parameter. - It deals with the drug's absorption and distribution rather than its interaction with the body once it reaches its site of action. *Transport of drug across the biological membranes* - The **transport of drugs across biological membranes** is a key aspect of **pharmacokinetics**, specifically absorption and distribution [1]. - This process determines how much drug reaches its target site, not how it interacts with the target. *Mode of excretion of a drug* - The **mode of excretion** of a drug (e.g., renal, hepatic) falls under **pharmacokinetics**, addressing how the body gets rid of the drug. - This process influences the drug's duration of action and elimination half-life, not its mechanism of action.

Question 2: A pregnant female at 37 weeks of gestation with a history of prosthetic heart valves is currently taking warfarin. She comes for a routine antenatal check-up. What is the appropriate management advice?

A. Immediate induction of labor
B. Perform LSCS (Lower Segment Cesarean Section)
C. Continue the same medication
D. Switch to low molecular weight heparin (Correct Answer)

Explanation: ***Switch to low molecular weight heparin*** - **Warfarin** is **teratogenic** and carries a significant risk of **fetal bleeding** and **malformations**, especially close to term. Switching to **low molecular weight heparin (LMWH)** is crucial at 37 weeks. - **LMWH** does not cross the placenta, making it a safer alternative for anticoagulation in late pregnancy for women with prosthetic heart valves. *Immediate induction of labor* - While delivery is approaching, immediate induction of labor without addressing the **warfarin** use directly puts the fetus at high risk of **bleeding complications** during delivery. - This option does not specify concurrent management of the anticoagulation, which is the primary concern. *Perform LSCS (Lower Segment Cesarean Section)* - Similar to induction of labor, performing a C-section while the mother is on **warfarin** significantly increases the risk of **maternal and fetal hemorrhage**. - A C-section is an invasive procedure, and the immediate priority is to switch the anticoagulant rather than select the mode of delivery without addressing the current medication. *Continue the same medication* - Continuing **warfarin** at 37 weeks is highly dangerous due to the increased risk of **fetal intracranial hemorrhage** during labor and delivery. - This approach disregards the well-established **teratogenic effects** and **bleeding risks** associated with warfarin in late pregnancy.

Question 3: A female patient of childbearing age is on valproate for JME. Which drug should be used to replace valproate and can be prescribed as monotherapy?

A. Carbamazepine
B. Phenytoin
C. Levetiracetam (Correct Answer)
D. Zonisamide

Explanation: ***Levetiracetam*** - **Levetiracetam** is recommended as a safer alternative to valproate in women of childbearing potential due to its **favorable pregnancy safety profile** and broad-spectrum efficacy against generalized seizures, including those seen in **juvenile myoclonic epilepsy (JME)** [1]. - It can be used as **monotherapy** and has a generally well-tolerated side effect profile [1], making it a suitable long-term option.*Carbamazepine* - **Carbamazepine** is primarily effective for **focal (partial) seizures** and is generally not recommended for **generalized epilepsy syndromes** like JME due to the risk of worsening myoclonic or absence seizures. - It also has significant **teratogenic risks**, including neural tube defects, making it unsuitable for women of childbearing age when safer alternatives exist [2].*Phenytoin* - **Phenytoin** is effective for focal and tonic-clonic seizures but can **exacerbate myoclonic seizures** in JME. - It carries a significant risk of **teratogenicity**, including fetal hydantoin syndrome, making it an inappropriate choice for women of childbearing potential [2].*Zonisamide* - **Zonisamide** is a broad-spectrum antiepileptic drug, but it is often reserved as an **add-on therapy** for refractory epilepsy rather than a first-line monotherapy, particularly if there are safer and more established first-line options. - While generally considered less teratogenic than valproate, its safety profile in pregnancy has fewer established data compared to levetiracetam.

Question 4: Caution is taken while doing Inter-maxillary Fixation (IMF) for which of these types of patients?

A. Psychiatric disorders
B. All of the options (Correct Answer)
C. Substance abusers
D. Epileptics

Explanation: ***All of the options*** - All of these patient groups require extra caution during IMF due to potential complications during the period of jaw immobilization. - For patients with **psychiatric disorders**, **substance abuse**, or **epilepsy**, the risks associated with IMF often outweigh the benefits, necessitating careful assessment and alternative treatment strategies. *Psychiatric disorders* - Patients with psychiatric disorders may have difficulty tolerating the **entrapment** feeling of IMF. - They also have a higher risk of **non-compliance** and may attempt to remove the fixation. *Substance abusers* - **Vomiting** is common in substance abusers, which can lead to **aspiration** if the jaw is wired shut. - These patients may also be **non-compliant** with post-operative care instructions, jeopardizing treatment outcomes. *Epileptics* - **Seizures** during IMF can lead to serious complications, including **aspiration** if vomiting occurs. - The forceful jaw movements during a seizure can also cause **fracture of the teeth** or damage to already **repaired jaw bones**.

Question 5: Which study design is most effective for investigating rare adverse effects of a drug?

A. Cohort study
B. Cross-sectional study
C. Case-control study (Correct Answer)
D. Clinical trial/experimental study

Explanation: ***Case-control study*** - This design starts by identifying individuals with the **rare adverse effect (cases)** and a control group without the effect to look back for exposure to the drug. - It is efficient for studying rare outcomes because it doesn't require following a large population for a long time to observe few events. *Cohort study* - A **cohort study** follows a group of individuals exposed and unexposed to a drug forward in time to observe outcomes. - While good for common outcomes, it would require an **extremely large sample size** and a long follow-up period to observe rare adverse drug effects. *Cross-sectional study* - A **cross-sectional study** assesses exposure and outcome simultaneously at a single point in time. - This design is suitable for determining **prevalence** but cannot establish temporal relationships between drug exposure and rare adverse effects, nor is it efficient for rare outcomes. *Clinical trial/experimental study* - **Clinical trials** are primarily designed to test the efficacy and safety of new interventions, usually focusing on common adverse effects. - They are generally **not powered** or long enough to detect rare adverse events, as such events would occur in very few participants, if any.

Question 6: What is the most common gastrointestinal side effect of oral contraceptives?

A. Decreased appetite
B. Weight loss
C. Nausea (Correct Answer)
D. Constipation

Explanation: ***Nausea*** - **Nausea** is a very common gastrointestinal side effect of oral contraceptives, especially during the initial weeks of use, due to the **estrogen component**. - This side effect often **improves over time** as the body adjusts, or can be managed by taking the pill with food or at bedtime. *Weight loss* - Oral contraceptives are **not typically associated with weight loss**; in fact, some users may experience slight weight gain, although studies show no consistent significant effect. - Changes in weight are more often due to **fluid retention** rather than true fat loss. *Decreased appetite* - **Decreased appetite** is not a common side effect of oral contraceptives; rather, some individuals might experience an increased appetite due to hormonal fluctuations. - The hormonal effects on metabolism and appetite are **varied and not consistently demonstrated** to lead to decreased appetite. *Constipation* - **Constipation** is not a frequent gastrointestinal side effect of oral contraceptives; rather, some users may experience changes in bowel habits, but **diarrhea is more commonly reported** than constipation when GI issues occur. - Hormonal contraceptives primarily affect the gut through **estrogen and progestin**, leading to various effects, but constipation is not a predominant one.

Question 7: Therapeutic drug monitoring is done for:

A. Aspirin
B. Heparin
C. Phenytoin (Correct Answer)
D. Metformin

Explanation: ***Phenytoin*** - **Phenytoin** has a **narrow therapeutic window**, meaning the difference between an effective and a toxic dose is small, necessitating close monitoring. - Its **variable absorption** and **nonlinear pharmacokinetics** (saturable metabolism) make individual dosing adjustments critical to maintain therapeutic levels and avoid toxicity. *Aspirin* - **Aspirin** is generally not monitored via plasma levels for its analgesic or antiplatelet effects, as its therapeutic effects are often observed at doses where plasma monitoring is not practical or necessary. - Its primary therapeutic use as an **antiplatelet agent** is evaluated by clinical outcomes rather than drug concentration. *Heparin* - **Heparin** is monitored using coagulation tests like **aPTT (activated partial thromboplastin time)** or anti-Xa levels to assess its anticoagulant effect, not direct drug concentration. - Therapeutic drug monitoring for heparin focuses on its **pharmacodynamic effects** on the clotting cascade rather than its absolute plasma concentration. *Metformin* - **Metformin** has a relatively **wide therapeutic index** and its efficacy is primarily measured by reductions in blood glucose and HbA1c, not by plasma drug concentrations. - It is excreted largely unchanged by the kidneys, and dose adjustments are typically made based on **renal function** and glycemic control.

Question 8: Match the following drugs in Column A with their contraindications in Column B. | Column A | Column B | | :-- | :-- | | 1. Morphine | 1. QT prolongation | | 2. Amiodarone | 2. Thromboembolism | | 3. Vigabatrin | 3. Pregnancy | | 4. Estrogen preparations | 4. Head injury |

A. A-1, B-3, C-2, D-4
B. A-4, B-1, C-3, D-2 (Correct Answer)
C. A-3, B-2, C-4, D-1
D. A-2, B-4, C-1, D-3

Explanation: ***A-4, B-1, C-3, D-2*** - **Morphine** is contraindicated in **head injury** as it can increase intracranial pressure and mask neurological symptoms. - **Amiodarone** is contraindicated in patients with **QT prolongation** due to its risk of inducing more severe arrhythmias like Torsades de Pointes. - **Vigabatrin** is contraindicated during **pregnancy** due to its potential for teratogenicity and adverse effects on fetal development. - **Estrogen preparations** are contraindicated in patients with a history of **thromboembolism** due to their increased risk of blood clot formation. *A-1, B-3, C-2, D-4* - This option incorrectly matches **Morphine** with QT prolongation and **Estrogen preparations** with head injury, which are not their primary contraindications. - It also incorrectly links **Vigabatrin** with thromboembolism and **Amiodarone** with pregnancy. *A-3, B-2, C-4, D-1* - This choice incorrectly associates **Morphine** with pregnancy and **Vigabatrin** with head injury, which are not the most critical or direct contraindications. - It also misaligns **Amiodarone** with thromboembolism and **Estrogen preparations** with QT prolongation. *A-2, B-4, C-1, D-3* - This option incorrectly matches **Morphine** with thromboembolism and **Amiodarone** with head injury, which are not their most significant contraindications. - It also incorrectly links **Vigabatrin** with QT prolongation and **Estrogen preparations** with pregnancy.

Question 9: ASA classification is done for – a) Status of patient b) Risk c) Pain d) Lung disease

A. ac
B. a
C. ab (Correct Answer)
D. bc

Explanation: ***ab*** - The **American Society of Anesthesiologists (ASA) Physical Status Classification System** is used to assess a patient's **overall health (status)** before surgery. - This classification helps in determining the **anesthetic risk** and guides anesthetic management. *ac* - While patient status is assessed, ASA classification does not primarily classify **pain** or pain management strategies. - **Lung disease** can influence a patient's ASA status, but it's not the sole or primary factor being classified independently. *a* - The ASA classification evaluates the patient's **overall health or status** but significantly aims to assess the **risk** associated with anesthesia and surgery. - Without considering risk, the classification loses its primary purpose in surgical planning. *bc* - The ASA system is indeed used to stratify **risk** for anesthesia and surgery, but it primarily does this by categorizing the patient's **overall physical status**. - It does not directly classify **pain** as an independent variable; patient conditions causing pain would contribute to their overall status.

Question 10: A 30-year-old woman is diagnosed with gonorrhea and reports a penicillin allergy (rash). Which alternative treatment regimen is most appropriate?

A. Azithromycin 2g orally single dose
B. Cefixime 400mg orally single dose
C. Ciprofloxacin 500mg orally single dose
D. Spectinomycin 2g IM single dose (Correct Answer)

Explanation: ***Spectinomycin 2g IM single dose*** - **Spectinomycin** is a safe and effective alternative for treating uncomplicated gonorrhea in patients with a history of severe penicillin or cephalosporin allergy. - It provides bactericidal activity against *Neisseria gonorrhoeae* and is administered as a **single intramuscular injection**. *Azithromycin 2g orally single dose* - While azithromycin is part of the dual therapy for gonorrhea (with ceftriaxone), using it as a **monotherapy** is not recommended due to increasing rates of resistance. - The CDC no longer recommends 2g azithromycin monotherapy for gonorrhea due to concerns about **macrolide resistance**. *Cefixime 400mg orally single dose* - **Cefixime** is a third-generation cephalosporin, and a penicillin allergy (especially a rash) may indicate a risk of **cross-reactivity** with cephalosporins. - While it's an alternative, it's generally avoided in significant penicillin allergy due to the potential for hypersensitivity reactions [1] and may have **lower efficacy** than ceftriaxone [2]. *Ciprofloxacin 500mg orally single dose* - **Ciprofloxacin** is a fluoroquinolone, and its use for gonorrhea is no longer recommended due to widespread and increasing **quinolone resistance** of *Neisseria gonorrhoeae* [2]. - Treatment with ciprofloxacin is associated with unacceptably high rates of **treatment failure** in many regions.

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free